Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS (GLUT-HEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02014883

Recruitment Status : Completed

First Posted : December 18, 2013

Last Update Posted : August 25, 2021

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Ultragenyx Pharmaceutical Inc

Information provided by (Responsible Party):

Institut National de la Santé Et de la Recherche Médicale, France

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	July 4, 2019
Actual Study Completion Date :	July 4, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mochel F, Hainque E, Gras D, Adanyeguh IM, Caillet S, Heron B, Roubertie A, Kaphan E, Valabregue R, Rinaldi D, Vuillaumier S, Schiffmann R, Ottolenghi C, Hogrel JY, Servais L, Roze E. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry. 2016 May;87(5):550-3. doi: 10.1136/jnnp-2015-311475. Epub 2015 Nov 3.

To Top